ReviewCancers2022
The Application of Magnetic Nanoparticles for Sentinel Lymph Node Detection in Clinically Node-Negative Breast Cancer Patients: A Systemic Review and Meta-Analysis.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Superparamagnetic Iron Oxide Tracer: A Magnetic Match to Gold Standard in Melanoma Sentinel Lymph Node Biopsy-A Systematic Review and Meta-Analysis.Journal of surgical oncology · 2025Pooled it
- New techniques versus standard mapping for sentinel lymph node biopsy in breast cancer: a systematic review and meta-analysis.Updates in surgery · 2023Pooled it
- Sentinel lymph node detection in early-stage breast cancer - Are technetium-99m-nanocolloid and superparamagnetic iron oxide diagnostically equivalent procedures? A propensity score matched real world data analysis.Breast (Edinburgh, Scotland) · 2026Article
- Optimization of Intraoperative Near-Infrared Fluorescence Mapping with Indocyanine Green for Sentinel Lymph Node Detection in Cervical and Endometrial Cancer.Pharmaceutics · 2026Article
- Dose Comparison (1 mL versus 2 mL) of Superparamagnetic Tracer for Sentinel Node Biopsy in Early Breast Cancer: Real-World Analysis from 456 Patients.Breast care (Basel, Switzerland) · 2026Article
- Sentinel lymph node biopsy with blue dye after neoadjuvant chemotherapy in initially node negative and positive breast cancer.World journal of surgical oncology · 2025Article
- Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study.The British journal of surgery · 2025Article
- The Effectiveness of Superparamagnetic Iron Oxide Nanoparticles in Reducing Unnecessary Sentinel Lymph Node Biopsies.Annals of surgical oncology · 2025Article
- Machine-learning methods based on the texture and non-texture features of MRI for the preoperative prediction of sentinel lymph node metastasis in breast cancer.Translational cancer research · 2023Article
- Role of Nuclear Sentinel Lymph Node Mapping Compared to New Alternative Imaging Methods.Journal of personalized medicine · 2023Review
- Iron and Cancer: A Special Issue.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Superparamagnetic iron oxide (SPIO), an alternative mapping agent, can be used to identify sentinel lymph nodes in patients with clinically node-negative breast cancer. However, its performance in comparison with the standard method, using a radioisotope (technetium-99 m, Tc) alone or in combination with blue dye, remains controversial. Hence, a systematic review and meta-analysis were conducted to evaluate the diagnostic accuracy of SPIO and its clinical impact in the management of breast cancer. The PubMed, Embase, and Cochrane databases were comprehensively searched from inception to 1 May 2022. Cohort studies regarding the comparison of SPIO with standard methods for sentinel lymph node identification were included. A total of 19 prospective cohort studies, which collectively included 2298 clinically node-negative breast cancer patients undergoing sentinel lymph node identification through both the standard method and SPIO, were identified. The detection rate for sentinel lymph nodes (RR, 1.06; 95% CI, 1.05−1.08; p < 0.001) was considerably higher in the SPIO cohorts than in the standard method cohorts, although this difference was not significant in detected patients, patients with positive sentinel lymph nodes, or positive sentinel lymph nodes. Compared with the standard method, the SPIO method could be considered as an alternative standard of care for sentinel lymph node detection in patients with clinically node-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.